Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
Public ClinicalTrials.gov record NCT03512210. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To achieve global hepatitis C virus (HCV) elimination by 2030, 80% of the \~71 million people with chronic HCV infection will need to be treated, necessitating simplification of treatment delivery and associated laboratory monitoring without compromising efficacy or safety. The COVID-19 pandemic has further highlighted the need for innovative models of health care delivery that minimize face-to-face patient-provider contact. The purpose of this study was to evaluate the feasibility, safety, and efficacy of a minimal monitoring (MINMON) strategy to deliver interferon- and RBV-free, pan-genotypic DAA therapy to treat active HCV in HCV treatment naïve participants.
Study identification
- NCT ID
- NCT03512210
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 2018
- Primary completion
- Jul 29, 2020
- Completion
- Feb 27, 2021
- Last update posted
- Feb 3, 2022
2018 – 2021
United States locations
- U.S. sites
- 30
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS (31788) | Birmingham | Alabama | 35294 | — |
| University of Southern California (1201) | Los Angeles | California | 90033-1079 | — |
| UCLA CARE Center CRS (601) | Los Angeles | California | 90095 | — |
| Ucsd, Avrc Crs (701) | San Diego | California | 92103 | — |
| Ucsf Aids Crs (801) | San Francisco | California | 94110 | — |
| University of Colorado Hospital CRS (6101) | Aurora | Colorado | 80045 | — |
| Whitman Walker Health CRS (31791) | Washington D.C. | District of Columbia | 20009 | — |
| The Ponce de Leon Center CRS (5802) | Atlanta | Georgia | 30308 | — |
| Northwestern University CRS (2701) | Chicago | Illinois | 60611 | — |
| Rush Univ. Med. Ctr. ACTG CRS (2702) | Chicago | Illinois | 60612 | — |
| Johns Hopkins University CRS (201) | Baltimore | Maryland | 21205 | — |
| Massachusetts General Hospital (MGH) CRS (101) | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hosp. ACTG CRS (107) | Boston | Massachusetts | 02115 | — |
| Washington U CRS (2101) | St Louis | Missouri | 63110 | — |
| New Jersey Medical School Clinical Research Center CRS (31786) | Newark | New Jersey | 07103 | — |
| Weill Cornell Chelsea CRS (7804) | New York | New York | 10010 | — |
| Columbia Physicians and Surgeons CRS (30329) | New York | New York | 10032 | — |
| Weill Cornell Upton CRS (7803) | New York | New York | 10065 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787) | Rochester | New York | 14642 | — |
| Unc Aids Crs (3201) | Chapel Hill | North Carolina | 27514 | — |
| Greensboro CRS (3203) | Greensboro | North Carolina | 27401 | — |
| Univ. of Cincinnati CRS (2401) | Cincinnati | Ohio | 45267 | — |
| Case CRS (2501) | Cleveland | Ohio | 44106 | — |
| The Ohio State Univ. AIDS CRS (2301) | Columbus | Ohio | 43210 | — |
| Hosp. of the Univ. of Pennsylvania CRS (6201) | Philadelphia | Pennsylvania | 19104 | — |
| Pittsburgh CRS (1001) | Pittsburgh | Pennsylvania | 15213 | — |
| The Miriam Hospital ACTG CRS (2951) | Providence | Rhode Island | 02906 | — |
| Vanderbilt Therapeutics (VT) CRS (3652) | Nashville | Tennessee | 37204 | — |
| Trinity Health and Wellness Center CRS (31443) | Dallas | Texas | 75208 | — |
| Houston AIDS Research Team CRS (31473) | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03512210, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2022 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03512210 live on ClinicalTrials.gov.